Effeicacy and safety of mytoxantrone associated with flag scheme in patients with relapsed or refractory acute leukemia
International Journal of Development Research
Effeicacy and safety of mytoxantrone associated with flag scheme in patients with relapsed or refractory acute leukemia
Received 24th December, 2016; Received in revised form 07th January, 2017; Accepted 26th February, 2017; Published online 31st March, 2017
Copyright©2017, Alvarado Ibarra Martha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective: The objective of this investigation was determinate the complete remission, overall survival, disease-free survival and toxicity rates in patients with relapsed or refractory acute leukemia who received FLAG plus mitoxantrone (FLAG-MITO) chemotherapy. Patients and Methods: Prospective, experimental, longitudinal, unicentric, single-arm study. Oral fludarabine 30 mg/m2BSA, cytarabine 2000 mg/m2BSA, mitoxantrone 8 mg/m2BSA and granulocyte colony-stimulating factor 300 mg every 12 hours were administrated to patients with relapsed or refractory acute leukemia. Results: Twelve patients were analyzed, complete remission was found in 75%, median disease-free survival was 5 months and median overall survival was 6 months. Hematologic toxicity in 100% of the patients and one death during induction were observed. All patients were admitted to a febrile neutropenia protocol with central venous catheter as main infection site. Conclusion: We believe that the use of FLAG-MITO regimen is an effective and safe treatment, providing a window of remission to consider bone marrow transplantation.
